Effects of Cardiac Resynchronization Therapy With or Without a Defibrillator on Survival and Hospitalizations in Patients With New York Heart Association Class IV Heart Failure
Author(s) -
JoAnn Lindenfeld,
Arthur M. Feldman,
Leslie A. Saxon,
John Boehmer,
Peter E. Carson,
Jalal K. Ghali,
Inder S. Anand,
Steve Singh,
Jonathan S. Steinberg,
Brian E. Jaski,
Teresa DeMarco,
David Mann,
Patrick Yong,
Elizabeth Galle,
Fred Ecklund,
Michael R. Bristow
Publication year - 2006
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/circulationaha.106.629261
Subject(s) - medicine , cardiac resynchronization therapy , heart failure , hazard ratio , cardiology , defibrillation , clinical endpoint , randomized controlled trial , confidence interval , ejection fraction
Cardiac resynchronization therapy (CRT) alone or combined with an implantable defibrillator (CRT-D) has been shown to improve exercise capacity and quality of life and to reduce heart failure (HF) hospitalizations and mortality in patients with New York Heart Association (NYHA) class III and IV HF. There is concern that the device procedure may destabilize these very ill class IV patients. We sought to examine the outcomes of NYHA class IV patients enrolled in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial to assess the potential benefits of CRT and CRT-D.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom